Emergent Biosolutions EBS Ratios & Valuation
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| Profitability | |||||
| Gross margin | 56.1%+21.4pp | 34.7%+1.9pp | 32.8%-5.2pp | 38%— | |
| Free cash flow margin | 21.9%— | —— | —— | —— | |
| Efficiency | |||||
| Asset turnover | 0.5×-0.1× | 0.6×+0.2× | 0.4×+0.1× | 0.4×-0.2× | |
| Inventory turnover | 1×-1.1× | 2.1×+0.1× | 2.1×+0.1× | 2×— | |
| Liquidity | |||||
| Current ratio | 5×+1.3× | 3.7×+2.6× | 1×+0.1× | 1×-2.4× | |
| Quick ratio | 2.4×+0.6× | 1.8×+1.2× | 0.5×-0.2× | 0.7×-1.8× | |
| Cash ratio | 1.6×+0.9× | 0.7×+0.5× | 0.2×-0.4× | 0.5×-1.0× | |
| Leverage | |||||
| Debt-to-equity | 1.1×-0.3× | 1.4×0.0× | 1.4×+0.3× | 1×+0.5× | |
| Debt-to-assets | 0.4×0.0× | 0.5×0.0× | 0.5×0.0× | 0.5×+0.2× | |
| Per Share | |||||
| Book value per share | $9.22+1.2% | $9.11-28.2% | $12.68-54.2% | $27.70-7.0% | |
| Valuation | |||||
| Market capitalization | $411.74M+22.0% | $518M+316% | $124.52M-78.9% | $589.18M-74.8% | |
| Enterprise value | $834.84M-2.6% | $1.09B+22.3% | $890.32M-35.2% | $1.37B-47.9% | |
| Price / sales | 0.6×+0.3× | 0.5×+0.4× | 0.1×-0.4× | 0.5×-0.8× | |
| Price / book | 0.8×+0.2× | 1.1×+0.9× | 0.2×-0.2× | 0.4×-1.0× | |
| EV / sales | 1.2×+0.3× | 1×+0.2× | 0.8×-0.4× | 1.2×-0.3× | |
| Free cash flow yield | 34.3%— | —— | —— | —— |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Emergent Biosolutions's profit margins?
- Emergent Biosolutions (EBS) runs a 54.2% gross margin and a 15.0% operating margin, with a 9.6% net margin.
- Where do Emergent Biosolutions's ratios come from?
- Every ratio is computed from Emergent Biosolutions's SEC filings — trailing-twelve-month flows over period-end balances. Valuation multiples combine those fundamentals with market data, recomputed each period. Switch between quarterly, annual, and TTM, or open any ratio for its full history and peer comparisons.
